Novabridge Biosciences (NBP) SEC Filings — 2025
37 SEC filings for Novabridge Biosciences (NBP) in 2025.
Filings
- NovaBridge Biosciences Files 6-K for Q3 2025 — 6-K · Dec 18, 2025
- NovaBridge Biosciences Files 6-K for ESMO IO Poster Release — 6-K · Dec 10, 2025
- Novabridge Biosciences 6-K Filing — 6-K · Dec 4, 2025
- NovaBridge Biosciences Files 6-K, Incorporates Exhibits — 6-K · Oct 31, 2025
- NovaBridge Biosciences Files 6-K with Assignment Agreement — 6-K · Oct 30, 2025
- NovaBridge Biosciences Shareholder Approval Filed — 6-K · Oct 29, 2025
- I-Mab Announces Acquisition of Hong Kong Subsidiary — 6-K · Oct 28, 2025
- I-Mab Files 6-K, Incorporates Exhibits into F-3 — 6-K · Oct 24, 2025
- I-Mab Files 6-K for October 2025 — 6-K · Oct 23, 2025
- I-Mab Files 6-K, Incorporates Exhibit 99.1 — 6-K · Oct 22, 2025
- I-Mab Unveils New Business Model — 6-K · Oct 16, 2025
- I-Mab Files 6-K Report for Q2 2025 — 6-K · Oct 6, 2025
- I-Mab Schedules Extraordinary General Meeting for Oct 24 — 6-K · Sep 24, 2025
- I-Mab Appoints Wei Fu as Executive Chairman — 6-K · Sep 8, 2025
- I-Mab Appoints Two New Directors to Board — 6-K · Aug 25, 2025
- I-Mab Files 6-K with Q2 2025 Financial Results — 6-K · Aug 20, 2025
- I-Mab Files 6-K, Incorporates Exhibit 99.1 — 6-K · Aug 11, 2025
- I-Mab Announces Underwritten Offering of ADSs — 6-K · Aug 4, 2025
- I-Mab Reports Preliminary Cash of $165.6M as of June 30 — 6-K · Aug 1, 2025
- I-Mab Subsidiary Enters Equity Purchase Agreement — 6-K · Jul 17, 2025
- I-Mab Amends Prospectus for $21M Share Offering — 6-K · Jul 11, 2025
- I-Mab Presents Positive Givastomig Phase 1b Data at ESMO GI — 6-K · Jul 2, 2025
- I-Mab Presents Positive Givastomig Data at ESMO — 6-K · Jun 26, 2025
- I-Mab Regains Nasdaq Minimum Bid Price Compliance — 6-K · Jun 12, 2025
- I-Mab Files Investor Presentation for June 2025 — 6-K · Jun 2, 2025
- I-Mab Appoints Dr. Sean Cao to Board of Directors — 6-K · May 30, 2025
- I-Mab Reports Q1 2025 Financial Results — 6-K · May 15, 2025
- I-Mab Files 6-K Report for April 2025 — 6-K · Apr 30, 2025
- I-Mab Files Investor Presentation on April 4, 2025 — 6-K · Apr 4, 2025
- I-Mab Files 2024 Annual Report — 20-F · Apr 3, 2025
- I-Mab Files Form 6-K for S-8 Registration — 6-K · Mar 21, 2025
- I-Mab Files 6-K, Includes March 7 Press Release — 6-K · Mar 7, 2025
- I-Mab Files Investor Presentation on Feb 27, 2025 — 6-K · Feb 27, 2025
- I-Mab Announces Workforce Reduction Amid Pipeline Reprioritization — 6-K · Jan 29, 2025
- I-Mab Files Investor Presentation for January 13, 2025 — 6-K · Jan 13, 2025
- I-Mab Board Member Buys Company Shares — 6-K · Jan 8, 2025
- I-Mab Prioritizes Givastomig as Lead Clinical Program — 6-K · Jan 6, 2025